top banner imagetop banner mobile image

Presentations
Print Page  | E-mail Page  | RSS Feeds  | E-mail Alerts  | IR Contacts  | Financial Tear Sheet 

DateTitle
01/11/17
Download Documentation TX-004HR Vaginal Estradiol Has Negligible to Very Low Systemic Absorption of Estradiol
01/11/17
Download Documentation The REJOICE Trial: A Phase 3 Randomized, Controlled Trial Evaluating the Safety and Efficacy of a Novel Vaginal Estradiol Soft-Gel Capsule for Symptomatic Vulvar and Vaginal Atrophy
01/09/17
Download Documentation January 2017 Investor Update
12/08/16
Download Documentation TX-001HR Supplemental Replenish Trial Design And Topline Phase 3 Results
10/14/16
Download Documentation The Women’s Empower Survey: Women’s Knowledge and Treatment of Vulvar and Vaginal Atrophy (VVA) Remains Low Years after Previous Surveys
09/26/16
Download Documentation September 2016 Investor Update
08/22/16
Download Documentation August 2016 Investor Update
05/14/16
Download Documentation 2016 ACOG Annual Meeting Presentation
04/02/16
Download Documentation The REJOICE Trial: A Phase 3 Randomized Controlled Trial Evaluating the Safety and Efficacy of a Novel Vaginal Estradiol Softgel Capsule for Symptomatic Vulvar and Vaginal Atrophy (VVA)
04/01/16
Download Documentation TX-004HR Vaginal Estradiol Effectively Treats Vulvar and Vaginal Atrophy (VVA) With Negligible to Low Systemic Absorption
03/07/16
Download Documentation REJOICE Trial Data Presentation
02/25/16
Download Documentation Painful Sex, Why Women Do or Don’t Seek Treatment
02/25/16
Download Documentation Rejoice Trial: Evaluation of an Applicator-Free Vaginal Estradiol Softgel Capsule for the Treatment of Postmenopausal Dyspareunia Associated With Vulvar and Vaginal Atrophy (VVA)
01/21/16
Download Documentation January 2016 Investor Update
11/17/15
Download Documentation November 2015 Investor Update
10/23/15
Download Documentation September 2015 Investor Update
10/07/15
Download Documentation August 2015 Investor Update
09/01/15
Download Documentation Woman’s Attitudes and Behaviors towards Vulvar and Vaginal Atrophy (VVA)
05/04/15
Download Documentation Behaviors/Attitudes Towards Hormone Replacement Therapy (HRT) Treatment for Menopausal Women in 5 Major European Countries
05/01/15
Download Documentation Factors Influencing Treatment Decisions Among Menopausal Women in 5 European Countries
03/02/15
Download Documentation Menopausal Hormone Therapy (MHT) Usage: FDA-Approved MHT Has Decreased While Compounded Non-FDA-Approved MHT Has Increased
03/01/15
Download Documentation Vaginal Physical Examination Correlates with Vaginal Epithelial Cells and pH and Can be Used to Assess Treatment Efficacy
10/02/14
Download Documentation Women's Use and Knowledge of Custom-Compounded Bioidentical Hormones
10/01/14
Download Documentation Estimation of Compounded Menopausal Hormone Therapy Use in the USA Following the WHI
05/01/14
Download Documentation The REPLENISH TRIAL: Evaluating TX-001HR (The First Combination 17β-Estradiol/Natural Progesterone Capsule Using SYMBODA™Technology), a New Option for the Treatment of Menopausal Symptoms
10/01/13
Download Documentation Pharmacokinetics of the First Combination 17[beta]-Estradiol/Progesterone Capsule in Clinical Development for Menopausal Hormone Therapy
Get help downloading or viewing the above file types

CORPORATE PRESENTATION

 

PRIMARY TXMD CONTACTS

David DeLucia
Director, Investor Relations
TherapeuticsMD
6800 Broken Sound Parkway NW
3rd Floor
Boca Raton, FL 33487
561-961-1900 or
david.delucia@therapeuticsmd.com